Project Grant SB1HL182469
Award Date 9/1/25
Completion Date 8/31/26
Dollars Obligated $498K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55436, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research grant program (CFDA 93.837), awarded $793,956 to Resuscitation Innovations LLC, doing business as Advancedcpr Solutions LLC, for the project "HEAD UP CPR AND AORTIC OCCLUSION TO IMPROVE SURVIVAL AFTER REFRACTORY CARDIAC ARREST". This project grant, awarded on January 1, 2025 with a planned completion date of January 23, 2026, aims to develop and evaluate new treatments to improve...
- This federal Cooperative Agreement award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program provides $1,249,999.00 in funding to CPR Therapeutics Inc. to develop a novel integrated system to improve survival rates and long-term outcomes for patients experiencing cardiac arrest. The project aims to create a fully automated CPR system that combines precision-controlled chest compressions, optimized electrical countershock, and...
- CPR Therapeutics Inc. received a $512,000 National Science Foundation Project Grant award under the NSF Technology, Innovation, and Partnerships program to develop an automated multimodal cardiopulmonary resuscitation system. The one-year award will support preclinical research and optimization studies using a swine model of cardiac arrest to design a next-generation proof-of-concept prototype. The system aims to improve outcomes for sudden cardiac arrest patients by integrating multiple...
- This $2,394,542 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will fund a randomized controlled trial to test the effect of transferring patients resuscitated from out-of-hospital cardiac arrest to a specialty cardiac care center versus usual care. The study aims to: 1) estimate the impact of specialty cardiac care on functional recovery, 2) identify the minimum clinical and operational standards for specialty cardiac arrest...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA Program 93.837 - Cardiovascular Diseases Research) aims to develop a deep learning-based algorithm to remove cardiopulmonary resuscitation (CPR) artifacts from electrocardiogram (ECG) signals in automated external defibrillators (AEDs). The $752,495 award, active from June 1, 2025 to March 31, 2029, will fund the creation of a database of CPR-contaminated ECG data and the evaluation and optimization of the deep...
- This federal Project Grant award of $889,188.00 from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a new oxygen therapy called Intravenous Oxygen (IVO2) for treating cardiac arrest. The project aims to optimize the molecular structure of polymeric microbubbles that can safely deliver high volumes of oxygen intravenously, without risks of embolism or vascular obstruction. This innovative approach is...
- This $437,461 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), funded under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a novel stabilization catheter device for His pacing lead implantation. The goal is to improve the accuracy and ease of His bundle pacing, an emerging alternative cardiac resynchronization therapy (CRT) for heart failure patients. The project aims to refine a deployable suction-tipped lead...
- This $500,000 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of the Hemotago HATS-OFF (Hemotag Assessment for Short-Term Outcomes of Heart Failure) technology by Aventusoft LLC, a small disadvantaged business in Boca Raton, Florida. The HATS-OFF system provides a non-invasive, at-home method for long-term monitoring of heart failure patients to detect decompensation early and enable timely therapy...
- This Project Grant award, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), funds the development of Heartpoint Global's IntelliSent - a minimally invasive, adjustable pulmonary flow restrictor system for pediatric and congenital heart disease patients. The $1,771,084 award supports efforts to (1) downsize the IntelliSent device to be suitable for patients from birth, including preclinical testing, (2) complete...
- The federal Project Grant award, valued at $413,595, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports the development of a "Magnetic Rotational Platform for Coronary Lesions" by Unandup, LLC, a technology firm in St. Louis, Missouri. The project aims to create an innovative medical device technology that leverages magnetic fields to improve the treatment of severe coronary artery...